Physician profile
Lisa M Ryan
NPI 1316342843
$493.21
in general payments reported to CMS, 2019-2025
13 companies · $51.67 in 2025
The $51.67 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $100 · 2023: $49.18 · 2024: $30.21 · 2025: $51.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $131.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $146.98 | 2021-2023 | |
| Novo Nordisk INC | $98.04 | 2021-2025 | |
| Glaxosmithkline, LLC. | $45.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.35 | 2022-2023 | Gattex |
| Kowa Pharmaceuticals America, INC. | $29.49 | 2021 | |
| Amarin Pharma, INC. | $29.34 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.03 | 2021 | |
| Astellas Pharma US INC | $14.70 | 2021 | |
| Pfizer INC. | $14.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.47 | 2021 | |
| Amgen INC. | $14.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.06 | 2021 | |
| Merck Sharp & Dohme LLC | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.